Docosahexaenoic Acid News and Research

RSS

Docosahexaenoic acid or DHA is an omega-3 essential fatty acid. DHA is the most abundant essential fatty acid (polyunsaturated fatty acids, PUFAs) in the brain and retina.

Study: High intake of omega-3 fats can help prevent obesity-related chronic diseases

A study of Yup'ik Eskimos in Alaska, who on average consume 20 times more omega-3 fats from fish than people in the lower 48 states, suggests that a high intake of these fats helps prevent obesity-related chronic diseases such as diabetes and heart disease.

25 Mar 2011

Mercury in fish may not increase heart disease risk: Study

According to a new study Americans' level of exposure to mercury from sources such as fish is not associated with a higher risk of heart disease, stroke or other cardiovascular disease. This is in spite of the repeated proofs of neurological deficits in children and unborn babies due to mercury exposure.

24 Mar 2011

Eating fatty fish reduces blindness risk from AMD: Study

New research has shown that consuming omega-3 fatty acids that are most commonly found in oily fish such as tinned salmon and tuna, could prevent the onset of age-related macular degeneration (AMD), a condition that leads to the gradual loss of vision. The required amount may be as low as one to two portions of fish a week that can reduce the risk of sight loss by up to 42 per cent in older women, according to a new study. Earlier results have shown similar benefits in men. Omega 3, whose common form in food is Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) can also be taken as a supplement.

16 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

Avesthagen Limited announced completion of a landmark project for the development of AvestaDHA(TM) - a vegetarian source of DHA (docohexanoic acid) omega 3 essential fatty acid based on an innovative approach using naturally occurring microalgae.

17 Feb 2011

Five tips to lower cholesterol

An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk. This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal.

9 Feb 2011

Promising results from TheraTears Nutrition pilot trial in dry eye patients

Advanced Vision Research, Inc. today announced the publication in the journal Cornea of promising results from a pilot trial of dry eye patients taking TheraTears® Nutrition. The study demonstrated a reduction in dry eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears® Nutrition, an optimized blend of medical grade essential omega-3 oils, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and flaxseed oil.

25 Jan 2011

Positive PK study results from ECLIPSE trial against cardiovascular disease

Omthera Pharmaceuticals, a privately-held emerging specialty pharmaceuticals company, today announced data from its ECLIPSE trial, designed to evaluate the bioavailability of Epanova™, the Company's lead compound for the treatment of very high triglycerides, in comparison to Lovaza®, the leading prescription Omega 3.

10 Jan 2011

Omega-3 fatty acids may reduce inflammation, disease symptoms and cartilage degeneration

Omega-3 fatty acids from seafood may reduce inflammation, symptoms of gum disease and risk of abnormal heartbeats early after cardiac surgery. One type of omega-3, DHA (docosahexaenoic acid), may also have lasting benefits in visual function for years in children whose mothers consume sufficient prenatal DHA.

30 Dec 2010

Royal DSM to acquire Martek for $1,087 million

Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million.

21 Dec 2010

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Researchers at the University of Illinois at Chicago completed a review of previously published research on antidepressant benefits of Omega-3 essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The review comprised a meta-analysis of 15 randomized, double-blind, placebo-controlled studies in patients with depression and results were presented at the recent annual meeting of the American College of Neuropsychopharmacology.

16 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

ONC enters exclusive long term strategic agreement with Wilmar

Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.

14 Dec 2010

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

22 Nov 2010

Media has misrepresented facts about Omega-3 DHA Alzheimer's study, says Ocean Nutrition Canada

Several media outlets published articles last week suggesting that Omega-3 fish oil supplements fail to show positive results for Alzheimer's patients. This reporting by media outlets came after the Journal of the American Medical Association (JAMA) published the study "Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial", where researchers reported that "Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease."

11 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

DHA improves memory function in older adults with mild cognitive impairments

A study published in the November edition of Alzheimer's & Dementia: The Journal of the Alzheimer's Association suggests that taking docosahexaenoic acid (DHA) may improve memory and learning in older adults with mild cognitive impairments. This is promising news for many aging Americans who are searching for options to maintain memory and support overall cognitive health.

9 Nov 2010

Omthera initiates ECLIPSE study for treatment of high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.

9 Nov 2010

Study finds DHA supplementation does not reduce risk of AD

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.

26 Oct 2010

Docosahexaenoic Acid News and Research

Study: High intake of omega-3 fats can help prevent obesity-related chronic diseases

Mercury in fish may not increase heart disease risk: Study

Eating fatty fish reduces blindness risk from AMD: Study

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

Five tips to lower cholesterol

Promising results from TheraTears Nutrition pilot trial in dry eye patients

Positive PK study results from ECLIPSE trial against cardiovascular disease

Omega-3 fatty acids may reduce inflammation, disease symptoms and cartilage degeneration

Royal DSM to acquire Martek for $1,087 million

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

ONC enters exclusive long term strategic agreement with Wilmar

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Media has misrepresented facts about Omega-3 DHA Alzheimer's study, says Ocean Nutrition Canada

DHA protects brain tissue and promotes recovery in acute ischemic stroke

DHA improves memory function in older adults with mild cognitive impairments

Omthera initiates ECLIPSE study for treatment of high triglycerides

Study finds DHA supplementation does not reduce risk of AD

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News